Ceftazidime-avibactam: Difference between revisions
From IDWiki
(Created page with "== Background == * Brand name Avycaz === Mechanism of Action === * Ceftazidime is a third-generation cephalosporin * Avibactam ** Inhibitis class A, C, and some cla...") |
No edit summary |
||
Line 1: | Line 1: | ||
== |
==Background== |
||
* |
*Brand name Avycaz |
||
=== |
===Mechanism of Action=== |
||
* |
*[[Ceftazidime]] is a third-generation cephalosporin |
||
* |
*[[Avibactam]] |
||
** |
**Inhibitis class A, C, and some class D beta-lactamases, includign OXA-48 |
||
** |
**No activity against class B |
||
** |
**Reduces MIC to ceftazidime in most Enterobacterales including [[Pseudomonas]] |
||
** |
**Does not induce AmpC expression |
||
** |
**Slowly-reversible inhibitor that gets recycld |
||
=== |
===Spectrum of Activity=== |
||
* |
*GNBs |
||
** |
**Active against carbapenem resistant [[Enterobaceriaceaea]], including KPCs and AmpC lactamases- |
||
** |
**Restores activity with cefatzidime in [[Pseudomonas]] and other GNBs |
||
** |
**Poor activity against [[Acinetobacter]] and [[Stenotrophomonas]] |
||
===Pharmacokinetics and Pharmacodynamics=== |
|||
⚫ | |||
* |
*Short half-life 2.7 hours |
||
* |
*Low protein binding |
||
* |
*Primarily renally cleared |
||
⚫ | |||
* Ceftazidime-avibactam 2.5 g (2 g / 0.5 g) IV q8h, infused over 2 hours |
|||
=== Pediatric Dosing === |
|||
* 3 months to <6 months: ceftazidime 40 mg/kg plus avibactam 10 mg/kg IV q8h, infused over 2 hours |
|||
* 6 months to <18 years: ceftazidime 50 mg/kg plus avibactam 12.5 mg/kg IV q8h, infused over 2 hours |
Revision as of 13:37, 12 September 2020
Background
- Brand name Avycaz
Mechanism of Action
- Ceftazidime is a third-generation cephalosporin
- Avibactam
- Inhibitis class A, C, and some class D beta-lactamases, includign OXA-48
- No activity against class B
- Reduces MIC to ceftazidime in most Enterobacterales including Pseudomonas
- Does not induce AmpC expression
- Slowly-reversible inhibitor that gets recycld
Spectrum of Activity
- GNBs
- Active against carbapenem resistant Enterobaceriaceaea, including KPCs and AmpC lactamases-
- Restores activity with cefatzidime in Pseudomonas and other GNBs
- Poor activity against Acinetobacter and Stenotrophomonas
Pharmacokinetics and Pharmacodynamics
- Short half-life 2.7 hours
- Low protein binding
- Primarily renally cleared
Dosing
- Ceftazidime-avibactam 2.5 g (2 g / 0.5 g) IV q8h, infused over 2 hours
Pediatric Dosing
- 3 months to <6 months: ceftazidime 40 mg/kg plus avibactam 10 mg/kg IV q8h, infused over 2 hours
- 6 months to <18 years: ceftazidime 50 mg/kg plus avibactam 12.5 mg/kg IV q8h, infused over 2 hours